Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPIDH1M Vaccine in Recurrent Grade II Glioma
NCT02193347Phase 1Completed
- Start
- Jan 2016
- Primary completion
- Feb 2020
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEPIDH1M in glioma. Primary endpoint: Percentage of Participants With an Unacceptable Toxicity. Started Jan 2016; status: completed.
02
Drugs
PEPIDH1M
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02193347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193347.